FR2824326B1 - Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications - Google Patents

Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications

Info

Publication number
FR2824326B1
FR2824326B1 FR0105980A FR0105980A FR2824326B1 FR 2824326 B1 FR2824326 B1 FR 2824326B1 FR 0105980 A FR0105980 A FR 0105980A FR 0105980 A FR0105980 A FR 0105980A FR 2824326 B1 FR2824326 B1 FR 2824326B1
Authority
FR
France
Prior art keywords
papillomavirus
peptides
proteins
applications
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0105980A
Other languages
English (en)
French (fr)
Other versions
FR2824326A1 (fr
Inventor
Bernard Maillere
Villada Isabelle Bourgault
Moratille Sandra Pouvelle
Jean Gerard Guillet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0105980A priority Critical patent/FR2824326B1/fr
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Priority to US10/476,570 priority patent/US7488791B2/en
Priority to PCT/FR2002/001533 priority patent/WO2002090382A2/fr
Priority to EP02730391A priority patent/EP1383535A2/fr
Priority to CA 2446062 priority patent/CA2446062A1/fr
Priority to AU2002302713A priority patent/AU2002302713A1/en
Priority to JP2002587459A priority patent/JP2005505503A/ja
Publication of FR2824326A1 publication Critical patent/FR2824326A1/fr
Application granted granted Critical
Publication of FR2824326B1 publication Critical patent/FR2824326B1/fr
Priority to US12/347,471 priority patent/US20100203080A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
FR0105980A 2001-05-04 2001-05-04 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications Expired - Fee Related FR2824326B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR0105980A FR2824326B1 (fr) 2001-05-04 2001-05-04 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
PCT/FR2002/001533 WO2002090382A2 (fr) 2001-05-04 2002-05-03 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
EP02730391A EP1383535A2 (fr) 2001-05-04 2002-05-03 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
CA 2446062 CA2446062A1 (fr) 2001-05-04 2002-05-03 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
US10/476,570 US7488791B2 (en) 2001-05-04 2002-05-03 Mixture of peptides derived from E6 and/or E7 papillomavirus proteins and uses thereof
AU2002302713A AU2002302713A1 (en) 2001-05-04 2002-05-03 Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof
JP2002587459A JP2005505503A (ja) 2001-05-04 2002-05-03 Ｅ６及び／又はｅ７パピローマウイルスタンパク質に由来するペプチドの混合物並びにその使用
US12/347,471 US20100203080A1 (en) 2001-05-04 2008-12-31 Mixture of Peptides Derived from E6 and/or E7 Papillomavirus Proteins and Uses Thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0105980A FR2824326B1 (fr) 2001-05-04 2001-05-04 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications

Publications (2)

Publication Number Publication Date
FR2824326A1 FR2824326A1 (fr) 2002-11-08
FR2824326B1 true FR2824326B1 (fr) 2004-03-19

Family

ID=8862980

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0105980A Expired - Fee Related FR2824326B1 (fr) 2001-05-04 2001-05-04 Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications

Country Status (7)

Country Link
US (2) US7488791B2 (OSRAM)
EP (1) EP1383535A2 (OSRAM)
JP (1) JP2005505503A (OSRAM)
AU (1) AU2002302713A1 (OSRAM)
CA (1) CA2446062A1 (OSRAM)
FR (1) FR2824326B1 (OSRAM)
WO (1) WO2002090382A2 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105554A (en) * 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
DE10336916B4 (de) * 2003-08-07 2015-02-19 Danfoss A/S Regelventil und Wärmetauscheranordnung
WO2006037059A2 (en) * 2004-09-27 2006-04-06 The Johns Hopkins Universtiy Point-of-care mass spectrometer system
JP2008044848A (ja) * 2004-11-30 2008-02-28 Univ Kurume Ｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
US7972776B2 (en) * 2005-11-15 2011-07-05 Oncohealth Corporation Protein chips for HPV detection
ES2310072B1 (es) * 2005-12-23 2009-11-16 Proyecto De Biomedicina Cima, S.L. Nuevos peptidos determinantes antigenicos t colaboradores (/dth).
US8968995B2 (en) * 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8859218B2 (en) 2008-06-13 2014-10-14 Oncohealth Corp. In situ detection of early stages and late stages HPV infection
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2013205259B2 (en) * 2007-05-31 2015-06-11 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
JP6035503B2 (ja) 2007-05-31 2016-11-30 アカデミシュ ジーケンハウス ライデン ハー．オー．デー．エン． ルムク ワクチンで使用するための、子宮頸部悪性腫瘍に浸潤するｔ細胞によって標的とされるｈｐｖエピトープ
KR20090103571A (ko) * 2008-03-28 2009-10-01 바이오코아 주식회사 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
CN102449479B (zh) 2009-05-07 2015-11-25 安科健康公司 鉴别高度或≥cin2用于人乳头瘤病毒(hpv)与hpv相关癌症的早期及晚期检测、筛检和诊断
AR074485A1 (es) * 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
JP5819851B2 (ja) 2010-01-08 2015-11-24 オンコヘルス コーポレーション Ｈｐｖ関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力ｈｐｖ免疫アッセイ
CN102060929A (zh) * 2010-06-07 2011-05-18 夏书奇 T细胞免疫平衡肽
CN103282375B (zh) 2010-12-02 2017-01-11 比奥诺尔免疫有限公司 肽支架设计
BR112014027957A8 (pt) 2012-05-08 2018-01-16 Univ Johns Hopkins métodos e composições para infusão de populações selecionadas de enxerto transitório de linfócitos alogênicos para tratar câncer"
US10286064B2 (en) 2012-06-15 2019-05-14 Pds Biotechnology Corporation Cationic lipid vaccine compositions and methods of use
TWI672149B (zh) 2012-09-21 2019-09-21 美商Ｐｄｓ生技公司 改良之疫苗組成物及使用方法
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
EP3058956A1 (en) 2015-02-23 2016-08-24 Institut Curie Combined vaccination/radioterapy for cancer treatment
EP4092112A1 (en) 2015-11-13 2022-11-23 PDS Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
CN117018170A (zh) 2016-06-20 2023-11-10 Isa制药有限公司 肽疫苗制剂
EP3267119A1 (en) 2016-07-07 2018-01-10 E.ON Sverige AB Combined heating and cooling system
EP3522908A4 (en) * 2016-10-05 2020-06-24 PDS Biotechnology Corporation INNOVATIVE HPV16 NON-HLA-RESTRICTED T-CELL VACCINES, COMPOSITIONS AND METHODS FOR USE THEREOF
AU2018378588A1 (en) 2017-12-05 2020-06-25 Pds Biotechnology Corporation Methods and compositions comprising cationic lipids for stimulating type 1 interferon genes
EP3743436A4 (en) * 2018-01-24 2021-10-27 The Council Of The Queensland Institute Of Medical Research HPV IMMUNOTHERAPY
KR20210005646A (ko) * 2018-04-26 2021-01-14 아게누스 인코포레이티드 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
CN113347987A (zh) * 2018-11-28 2021-09-03 总医院公司 针对共生病毒的t细胞导向的抗癌疫苗
US20230100653A1 (en) * 2020-02-10 2023-03-30 The Johns Hopkins University Cancer immunotherapy using transfusions of allogeneic, tumor-specific cd4+ t cells
EP4281106A4 (en) * 2021-01-21 2024-12-25 The General Hospital Corporation T-CELL-TARGETED ANTICANCER VACCINES AGAINST COMMENSAL VIRUSES FOR THE TREATMENT OF MUCOSAIC CARCINOMAS
WO2024223299A2 (en) 2023-04-26 2024-10-31 Isa Pharmaceuticals B.V. Methods of treating cancer by administering immunogenic compositions and a pd-1 inhibitor
CN119569831B (zh) * 2024-12-13 2026-04-28 深圳锦时生物科技有限公司 一种活性多肽及在预防和/或治疗hpv中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932412A (en) * 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
ES2193133T3 (es) * 1991-07-13 2003-11-01 Dade Behring Marburg Gmbh Uso de peptidos derivados de los genes e6 y e7 de hpv-16 para fines.
CO4600681A1 (es) * 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
CA2317724A1 (en) * 1998-01-09 1999-07-15 Circassia Limited Methods and compositions for desensitisation
FR2794370B1 (fr) * 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
WO2001021189A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
SE9903031D0 (sv) * 1999-08-27 1999-08-27 Eurodiagnostica Ab Peptide mixture and vaccine against a chronic viral infection
US20050100928A1 (en) * 1999-09-16 2005-05-12 Zycos Inc., A Delaware Corporation Nucleic acids encoding polyepitope polypeptides
EP2100620A1 (en) * 1999-09-16 2009-09-16 Eisai Corporation of North America Nucleic acids encoding polyepitope polypeptides
AU1075001A (en) * 1999-10-05 2001-05-10 Epimmune, Inc. Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions

Also Published As

Publication number Publication date
US20040170644A1 (en) 2004-09-02
WO2002090382A3 (fr) 2003-10-02
EP1383535A2 (fr) 2004-01-28
US20100203080A1 (en) 2010-08-12
FR2824326A1 (fr) 2002-11-08
US7488791B2 (en) 2009-02-10
CA2446062A1 (fr) 2002-11-14
AU2002302713A1 (en) 2002-11-18
WO2002090382A2 (fr) 2002-11-14
JP2005505503A (ja) 2005-02-24

Similar Documents

Publication Publication Date Title
AU2002302713A1 (en) Mixture of peptides derived from e6 and/or e7 papillomavirus proteins and uses thereof
EP1576130A4 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS NAMED 282P1G3 WITH FITNESS FOR THE TREATMENT AND DETECTION OF CANCER
EP1549768A4 (en) MICROFLUIDIC PROTEIN CRYSTALLOGRAPHY
HUE044812T2 (hu) Prolinspecifikus endoproteázok alkalmazása peptidek és fehérjék hidrolízisére
EP1470159A4 (en) ANTIBODIES AGAINST LATENT MEMBRANE PROTEINS AND USES THEREOF
EP1424392A4 (en) NEW SECRETIONAL PROTEINS AND DNA FOR THEM
EP1543038A4 (en) PROTEIN PURIFICATION
MA26314A1 (fr) Concentrés de proteines de lait modifiees et leur utilisation dans la fabrication de gels et de produits laitiers
DE60238576D1 (de) Zusammensetzung zur Herstellung von Elektroden und Elektroden
EP1711650A4 (en) MICROFLUIDIC PROTEIN CRYSTALLOGRAPHIC METHODS
AU2003253784A1 (en) Peptides from the e2, e6 and e7 proteins of human papillomaviruses 16 and 18 for detecting and/or diagnosing cervical and other cancers
IL158126A0 (en) Peptides and antibodies to muc 1 proteins
AU2002219960A1 (en) Molecules of the card-related protein family and uses thereof
DE60232862D1 (de) Rekombinantes pockenvirus für chimäre proteine des menschlichen immunschwächevirus
EP1578774A4 (en) PROTEIN PURIFICATION
EP1464701A4 (en) Fluorescent proteins
AU2002362604A1 (en) Novel molecules of the pyrin domain protein family and uses thereof
IL160396A0 (en) Nucleic acids and proteins of insect or83b odorant receptor genes and uses thereof
EP1682572A4 (en) Protein Expression
EP1435996A4 (en) COMPOSITIONS WITH MIXTURE THERAPEUTIC PROTEINS AND METHOD FOR THE PRODUCTION THEREOF
IL158860A0 (en) Nucleic acids and corresponding proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer and pharmaceutical compositions containing the same
AU2002362414A1 (en) Novel molecules of the hkid-1-related protein family and uses thereof
EP1539949A4 (en) RAR1 DISEASE RESISTANT PROTEIN CODING NUCLEIC ACID MOLECULES FROM RICE AND USES THEREOF
AU1572702A (en) Novel immunomodulatory protein and useful embodiments thereof
AU2001273287A1 (en) Large scale expression and purification of recombinant proteins

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20140131